Marx N - Search Results

1

Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies.

Lehrke M, Marx N, Patel S, Seck T, Crowe S, Cheng K, von Eynatten M, Johansen OE. Lehrke M, et al. Among authors: marx n. Clin Ther. 2014 Aug 1;36(8):1130-46. doi: 10.1016/j.clinthera.2014.06.008. Epub 2014 Jul 8. Clin Ther. 2014. PMID: 25015594 Free article.

2

Cardiovascular effects of incretin-based therapies.

Lehrke M, Marx N. Lehrke M, et al. Among authors: marx n. Rev Diabet Stud. 2011 Fall;8(3):382-91. doi: 10.1900/RDS.2011.8.382. Epub 2011 Nov 10. Rev Diabet Stud. 2011. PMID: 22262075 Free PMC article. Review.

3

[Cardiovascular effects of incretin-based therapies].

Lehrke M, Marx N. Lehrke M, et al. Among authors: marx n. Herz. 2012 May;37(3):287-93. doi: 10.1007/s00059-012-3599-8. Herz. 2012. PMID: 22430284 German.

4

Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes?

Burgmaier M, Heinrich C, Marx N. Burgmaier M, et al. Among authors: marx n. Diabet Med. 2013 Mar;30(3):289-99. doi: 10.1111/j.1464-5491.2012.03746.x. Diabet Med. 2013. PMID: 22804451 Review.

5

New antidiabetic therapies: innovative strategies for an old problem.

Lehrke M, Marx N. Lehrke M, et al. Among authors: marx n. Curr Opin Lipidol. 2012 Dec;23(6):569-75. doi: 10.1097/MOL.0b013e328359b19f. Curr Opin Lipidol. 2012. PMID: 23069986 Review.

6

Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial.

Rosenstock J, Marx N, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Bluhmki E, Patel S, Johansen OE, Woerle HJ. Rosenstock J, et al. Among authors: marx n. Diab Vasc Dis Res. 2013 Jul;10(4):289-301. doi: 10.1177/1479164112475102. Epub 2013 Feb 28. Diab Vasc Dis Res. 2013. PMID: 23449634 Free article. Review.

7

Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans.

Piotrowski K, Becker M, Zugwurst J, Biller-Friedmann I, Spoettl G, Greif M, Leber AW, Becker A, Laubender RP, Lebherz C, Goeke B, Marx N, Parhofer KG, Lehrke M. Piotrowski K, et al. Among authors: marx n. Cardiovasc Diabetol. 2013 Aug 16;12:117. doi: 10.1186/1475-2840-12-117. Cardiovasc Diabetol. 2013. PMID: 23953602 Free PMC article.

8

Glucagon-like peptide-1 (GLP-1) and its split products GLP-1(9-37) and GLP-1(28-37) stabilize atherosclerotic lesions in apoe⁻/⁻ mice.

Burgmaier M, Liberman A, Möllmann J, Kahles F, Reith S, Lebherz C, Marx N, Lehrke M. Burgmaier M, et al. Among authors: marx n. Atherosclerosis. 2013 Dec;231(2):427-35. doi: 10.1016/j.atherosclerosis.2013.08.033. Epub 2013 Sep 5. Atherosclerosis. 2013. PMID: 24267262

9

GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering.

Kahles F, Meyer C, Möllmann J, Diebold S, Findeisen HM, Lebherz C, Trautwein C, Koch A, Tacke F, Marx N, Lehrke M. Kahles F, et al. Among authors: marx n. Diabetes. 2014 Oct;63(10):3221-9. doi: 10.2337/db14-0100. Epub 2014 Jun 19. Diabetes. 2014. PMID: 24947356

10

PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner.

Lehrke M, Kahles F, Makowska A, Tilstam PV, Diebold S, Marx J, Stöhr R, Hess K, Endorf EB, Bruemmer D, Marx N, Findeisen HM. Lehrke M, et al. Among authors: marx n, marx j. J Mol Cell Cardiol. 2015 Apr;81:23-33. doi: 10.1016/j.yjmcc.2015.01.015. Epub 2015 Jan 30. J Mol Cell Cardiol. 2015. PMID: 25640159

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

593 results

Search Page